US authorities arrest and charge the founder and the head doctor of telehealth company Done Global for an alleged scheme to profit from Adderall prescriptions
($100m adderall distribution and health care fraud scheme by a telehealth startup founded by former fb designer & backed by craft ventures and offline ventures, according to crunchbase) — https://www.justice.gov/... X: Tyson Brody / @tysonbrody : “Done's early investors included the venture firm of former Zenefits Inc. executive David Sacks. Sacks didn't immediately respond to a request for comment.” [image] Deva Hazarika / @devahaz : Chamath pushing SPACs, Sacks pushing adderall, what will the all-in guys have next for the people? @luke_metro : David Sacks? The former Zenefits executive? [image] LinkedIn: Mariana Ivanylo : California based digital health company Done and its clinical president were arrested on June 13 in connection with their alleged participation … Fritz Scanlon : Amazing work by Jacob Foster and Raymond E. Beckering III on this extremely significant matter. The Health Care Fraud unit is dedicated to rooting … Forums: Hacker News : SF startup bosses illegally peddled $100M in Adderall, Feds say r/news : SF startup execs arrested in $100M illegal Adderall scheme r/medicine : CEO and Clinical President of Done Telehealth arrested for Health Care Fraud r/pharmacy : Telehealth Stimulants 🤡
Context & Ripple Effects
The charges escalate concerns raised in earlier reporting that Done and Cerebral used looser pandemic-era prescribing rules and clinician pressure in their stimulant businesses. Earlier scrutiny of Done's prescribing practices had already put the telehealth model for ADHD treatment under a regulatory lens.
The case also links clinical compliance to startup governance: Done's early backing makes the allegations relevant not only to prescribers but to investors assessing oversight in regulated digital-health businesses. Subsequent coverage indicates the company remained operational after its owner's arrest, underscoring that enforcement action does not automatically resolve continuity-of-care and operating-control questions. Reporting on Done's continued operations after the arrest
First-order effects
- Done's founder and clinical president face criminal allegations tied to a purported Adderall distribution and health-care fraud scheme, placing the company and its prescribing practices under acute law-enforcement scrutiny.
- Patients, clinicians, and business partners connected to Done may face disruption or additional review as authorities examine the alleged prescription model.
Second-order effects
- Other telehealth providers serving ADHD patients will face stronger pressure to document clinical judgment, prescribing safeguards, and clinician independence—areas previously raised in reporting on stimulant-focused growth tactics. Cerebral's social-media-driven ADHD drug growth illustrates the adjacent model now exposed to greater scrutiny.
- Investors and boards in regulated health startups may give more weight to compliance controls and clinical governance, rather than treating rapid patient acquisition as a standalone growth signal.
Third-order effects
- If enforcement continues, pandemic-era telehealth prescribing flexibility may give way to a more compliance-intensive market in which controlled-substance care is harder to scale through standardized online workflows.
- The broader structural shift is toward digital-health companies being evaluated as health-care operators—with corresponding fraud, prescribing, and governance exposure—rather than primarily as consumer software businesses.
The trend: The case is one data point in the tightening accountability of telehealth businesses whose growth depends on prescribing regulated drugs at scale.